ストックスクリーナーアプリを入手
101.44
0.59%
-0.60
プレマーケット:
102.90
1.46
+1.44%
前日終値:
$102.04
開ける：
$102.41
24時間の取引高:
2.40M
Relative Volume:
1.15
時価総額：
$19.91B
収益：
$4.58B
当期純損益:
$870.87M
株価収益率:
23.06
EPS:
4.3988
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
-3.89%
1か月 パフォーマンス:
+8.52%
6か月 パフォーマンス:
+55.32%
1年 パフォーマンス:
+38.50%
1日の値動き範囲:
$100.55
$103.54
1週間の範囲:
$100.55
$107.00
52週間の値動き範囲:
$53.56
$109.28
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
101.44 | 20.03B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding - Business Wire
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel - BioSpace
Incyte (INCY): Evaluating Valuation Following Recent Share Price Momentum - Yahoo Finance
Incyte appoints Richard Hoffman as executive VP and general counsel By Investing.com - Investing.com Nigeria
Incyte (Nasdaq: INCY) appoints Richard Hoffman as Executive VP and General Counsel - Stock Titan
CACS Drug Market Accelerates at 3.9% CAGR to 2033, Reaching USD - openPR.com
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MyChesCo
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte: This Profitable Biotech Trades Like A Melting Iceberg (NASDAQ:INCY) - Seeking Alpha
Incyte: Riding Jakafi, Bracing For Generic Headwinds (NASDAQ:INCY) - Seeking Alpha
Incyte’s principal accounting officer Tray Thomas sells $79k in stock - Investing.com
Incyte receives the first letter confirming compliance following the FDA’s Untitled Letter spree - Medical Marketing and Media
Opzelura From Incyte Corp. - Pharmacy Times
Incyte Outpaces Expectations And Raises Its Revenue Forecast - Finimize
Incyte Corp. Stock Climbs 4.1%, Outperforms Peers - 富途牛牛
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know - Yahoo Finance
Incyte (INCY): Barclays Raises Price Target to $115, Maintains O - GuruFocus
Does Incyte's Expanding Drug Pipeline Signal an Opportunity Following a 46.8% Price Surge? - Yahoo Finance
Incyte (INCY) Tops Goldman Sachs' Hedge Fund Concentration List - GuruFocus
Officer Tray Files To Sell 169 Of Incyte Corp [INCY] - TradingView
Commit To Purchase Incyte At $87.50, Earn 12.3% Annualized Using Options - Nasdaq
Is Incyte Corporation (ICY) stock among top earnings playsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Incyte to Present at Upcoming December 2025 Investor Conferences - BioSpace
Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Is Incyte Corporation (ICY) stock considered safe havenJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Incyte at Jefferies London: Strategic Shift to Diversification - Investing.com
Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions - MyChesCo
Incyte Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
VP Denton Files To Sell 278 Of Incyte Corp [INCY] - TradingView
Is Incyte Corporation building a consolidation baseEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Incyte (INCY) Receives Positive Opinion for Minjuvi in Europe - GuruFocus
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - BioSpace
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Can Incyte Corporation (ICY) stock attract analyst upgradesEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com
Forecasting Incyte Corporation price range with options dataJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
STATE STREET CORP Reduces Stake in Incyte Corp: A Strategic Port - GuruFocus
What risks investors should watch in Incyte Corporation stockTreasury Yields & AI Powered Market Entry Ideas - newser.com
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Key metrics from Incyte Corporation’s quarterly dataJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why Analysts See Incyte’s Story Shifting as Pipeline Progress Drives New Valuation Targets - Yahoo Finance
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock see PE expansionQuarterly Growth Report & Weekly High Return Opportunities - newser.com
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Prepares to Showcase Pipeline Momentum With New mutCALR Data at ASH 2025 - MyChesCo
Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance
Incyte stock hits 52-week high at 108.81 USD By Investing.com - Investing.com Canada
Incyte stock hits 52-week high at 108.81 USD - Investing.com
Peering Into Incyte Corp's Recent Short Interest - Benzinga
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MSN
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
1.02%
1.31%
大文字化:
|
ボリューム (24 時間):